Jie Wan

Jie Wan

Auto-generated profile, based on publicly available information

Jie Wan

Hongqiao International Institute of Medicine, Tongren Hospital & Shanghai Institute of Immunology, Department of Immunology and Microbiology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
JWJie Wan
Jie Wan
JSJian-hong Shi
Jian-hong Shi
MSMin Shi
Min Shi
HHHaiyan Huang
Haiyan Huang
ZZZhen Zhang
Zhen Zhang
QZQiang Zou
Qiang Zou

1 January 2021 in Cancer Letters
Verified
Journal Article
Open access
HWHongsheng Wang
Hongsheng Wang
HZHuangao Zhou
Huangao Zhou
JXJianing Xu
Jianing Xu
YLYunpeng Lu
Yunpeng Lu
XJXiaoyun Ji
Xiaoyun Ji
JWJie Wan
Jie Wan
Glioblastoma multiforme (GBM) is a brain tumor with a high mortality rate. Surgical resection combined with radiotherapy and chemotherapy is the standard treatment for GBM patients, but the 5-year survival rate of patients despite this treatment is low. Immunotherapy has attracted increasing attention in recent years. As the pioneer and the main effector cells of immunotherapy, T cells play a key role in tumor immunotherapy. However, the T cells in GBM microenvironment are inhibited by the highly immunosuppressive environment of GBM, posing huge challenges to T cell-based GBM immunotherapy. This review summarizes the effects of the GBM microenvironment on the infiltration and function of different T-cell subsets and the possible strategies to overcome immunosuppression, and thus enhance the effectiveness of GBM immunotherapy.

1 May 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
WCWenli Chen
Wenli Chen
SYShun Yao
Shun Yao
JWJie Wan
Jie Wan
YTYu Tian
Yu Tian
LHLan Huang
Lan Huang
XZXiao chun Zhang
Xiao chun Zhang

8 August 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
XDXian Du
Xian Du
WLWenyan Li
Wenyan Li
GLGuiying Li
Guiying Li
CGChenyue Guo
Chenyue Guo
XTXuyi Tang
Xuyi Tang
QZQiang Zou
Qiang Zou

15 August 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHeng Li
Heng Li
CKClara K. T. Koh
Clara K. T. Koh
TZTianshuai Zhang
Tianshuai Zhang
YLYi Lu
Yi Lu
CPChin Wen Png
Chin Wen Png
YZYongliang Zhang
Yongliang Zhang
The activation and function of CD8+ T cells, which are central for anti-tumor immunity, are tightly regulated by extracellular and intracellular signaling pathways. Dual-specificity phosphatases (DUSP), including DUSP4, dephosphorylate serine/threonine and tyrosine residues of proteins to modulate cellular signaling. Here, we investigate the role of DUSP4 in cancer immunity. Patients with colorectal cancers (CRC) with lower DUSP4 expression across the CRC tissue exhibit shorter survival compared to those with higher DUSP4 expression. By contrast, in AOM/DSS-induced male mouse CRC models, global DUSP4 deficiency enhances tumorigenesis and compromises CD8+ T cell-mediated anti-tumor immunity. Mechanistically, DUSP4 knockout increases ERK2-mediated expression of the T cell activation regulator Klf2, thereby suppressing KLF2-mediated cytotoxic programs. In a CD19+ CRC xenograft mouse model, CRISPRa-mediated DUSP4 activation promotes anti-CD19 CAR-T cell proliferation and anti-tumor cytotoxicity. Thus, our data show that DUSP4 supports CD8+ T cell cytotoxic functions and suggest that DUSP4 may be a promising therapeutic target for enhancing anti-tumor immunity.